




R E M A R K S

Favorable comment on the application as amended herein is earnestly solicited. The examiner is kindly invited to contact the undersigned by telephone to discuss matters which may further the prosecution of this application or facilitate the allowability of some or all of the claims herein.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "**Version with Markings to Show Changes Made**".

Respectfully submitted,



Anthony J. Zelano (Reg. No. 27,969)
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza I
2200 Clarendon Boulevard, Suite 1400
Arlington, Virginia 22201
Direct Dial: (703) 812-5311
Facsimile No.: (703) 243-6410
Internet Address: zelano@mwzb.com

Filed: July 24, 2001

AJZ/njr
K:\Sch\1738\preliminar amendment 07.24.01.wpd



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 3-10, 12-14 and 17-24 have been amended as follows:

3. Benzimidazoles according to claim 1 or 2, wherein
 R^2 means a monocyclic or bicyclic C_{6-10} aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:
F, Cl, Br,
XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R⁴, XC(NO(COR⁴))R⁴,
XCOOH, XCOOR⁴, XCONH₂, XCONHR⁴, XCONR⁴R⁴, XCONHOH,
XCONHOR⁴, XCOSR⁴,
XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R⁴,
NO₂, XNHR⁴, XNR⁴R⁴, XNHSO₂R⁴, XN(SO₂R⁴)SO₂R⁴, XNR⁴SO₂R⁴, R⁴, whereby two substituents at R^2 , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.
4. Benzimidazoles according to one of claims 1-3 claim 1, wherein
 R^3 means one or two substituents, which, independently of one another, can be:
hydrogen, F, Cl, Br,
XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴, XC(NOR⁴)R⁴, XC(NO(COR⁴))R⁴,
XCN, XSR⁴, XSOR⁴, XSO₂R⁴, SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R⁴,
NO₂, XNH₂, XNHR⁴, XNR⁴N⁴,
XNHSO₂R⁴, XNR⁴SO₂R⁴, XN(SO₂R⁴)SO₂R⁴,

XNHCOR⁴, XNHCOOR⁴, XNHCONHR⁴, or R⁴, whereby two substituents R³, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxyl, ethane-1,2-diylbisoxyl, propane-1,3-diyl, or butane-1,4-diyl.

5. Benzimidazoles according to ~~one of claims 1-4~~ claim 1, wherein R⁴ and R^{4'}, independently of one another, mean CF₃, C₂F₅, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkinyl, C₃₋₆ cycloalkyl, (C₁₋₃ alkyl-C₃₋₆ cycloalkyl), phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the phenyl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH₃, C₂H₅, OCH₃, OC₂H₅, CF₃, C₂F₅, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl.
6. Benzimidazoles according to ~~one of claims 1-5~~ claim 1, wherein R⁵ and R^{5'}, independently of one another, can be C₁₋₆ alkyl, whereby a carbon atom can be exchanged for O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl, C₃₋₇ cycloalkyl-C₀₋₃ alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, whereby the mentioned C₁₋₆ alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF₃, OH, O C₁₋₃ alkyl, and the previously mentioned heteroaryl groups with one or two substituents

that consist of F, Cl, CF₃, CH₃, C₂H₅, OCH₃, OC₂H₅, or R⁵ and R^{5'} together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C₁₋₄ alkyl, C₁₋₄ alkoxy-C₀₋₂ alkyl, C₁₋₄ alkoxy-carbonyl, aminocarbonyl or phenyl.

7. Benzimidazoles according to ~~one of claims 1-6~~ claim 1, wherein
A means C₁₋₁₀ alkanediyl, C₂₋₁₀ alkenediyl, C₂₋₁₀ alkinediyl, (C₀₋₅ alkanediyl-C₃₋₇ cycloalkanediyl-C₀₋₅ alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, N C₁₋₃ alkyl, or N C₁₋₃ alkanoyl.
8. Benzimidazoles according to ~~one of claims 1-7~~ claim 1, wherein
B means COOH, COOR⁵, CONH₂, CONHR⁵, CONR⁵R^{5'}, CONHOH, CONHOR⁵ or tetrazolyl,
in each case bonded to a carbon atom of group **A**.
9. Benzimidazoles according to ~~one of claims 1-8~~ claim 1, wherein
X means a bond or methylene.
10. Benzimidazoles according to ~~one of claims 1-9~~ claim 1, wherein
Y means O.
12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester
6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester
6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

ester

6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid methyl ester

6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]butanoic acid methyl ester

5-[[5-[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[5-[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yloxy]pentanoic acid methyl ester

6-[[5-[(4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

6-[[5-[(4-chlorophenyl)sulfonyl)methylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid

6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yloxy]hexanoic acid methyl ester

N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yloxy]-hexanamide

N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yloxy]hexanamide

N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-(3-methoxypropyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]-1-morpholin-1-ylhexan-1-one

N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yloxy]hexanamide

N-isopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanamide

N,N-dimethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yloxy]hexanamide

N,N-diethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

N-isobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-tert-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

(R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one

N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide

6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H- benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

each a compound of claim 1.

13. Use of a compound according to ~~one of claims 1-12~~ claim 1 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

14. Pharmaceutical agent, wherein it contains one or more compounds according to ~~one of claims 1-12~~ claim 1 and one or more vehicles.

17. Use according to claim 15-~~or 16~~, whereby in general formula II,
 R^2 means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR⁴, XOCOR⁴, XOCONHR⁴, XOCOOR⁴,
XCOR⁴, XC(NOH)R⁴,
XC(NOR⁴)R⁴, XC(NO(COR⁴))R⁴, XCN, XCOOH, XCOOR⁴, XCONH₂,
XCONR⁴R⁴,
XCONHR⁴, XCONHOH, XCONHOR⁴, XCOSR⁴, XSR⁴, XSOR⁴, XSO₂R⁴,
SO₂NH₂, SO₂NHR⁴, SO₂NR⁴R⁴, NO₂, XNH₂, XNHR⁴, XNR⁴R⁴,
XNHSO₂R⁴,
XN(SO₂R⁴)(SO₂R⁴'), XNR⁴SO₂R⁴', XNHCOR⁴, XNHCOOR⁴,
XNHCONHR⁴, R⁴,

whereby two substituents at R^2 , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.

18. Use according to ~~claims 15-17~~ claim 15, whereby in general formula II R^3 stands for one or two substituents, which independently of one another, mean:
hydrogen,
 F , Cl , Br , XOH , XOR^4 , XOCOR^4 , XOCONHR^4 ,
 XOCOOR^4 , XCOR^4 , $\text{XC}(\text{NOH})\text{R}^4$, $\text{XC}(\text{NOR}^4)\text{R}^4$, $\text{XC}(\text{NO}(\text{COR}^4))\text{R}^4$,
 XCN , XSR^4 , XSOR^4 , XSO_2R^4 , SO_2NH_2 , SO_2NHR^4 , $\text{SO}_2\text{NR}^4\text{R}'$, NO_2 ,
 XNH_2 , XNHR^4 , $\text{XNR}^4\text{R}'$, XNHSO_2R^4 , $\text{XNR}^4\text{SO}_2\text{R}'$, $\text{XN}(\text{SO}_2\text{R}^4)(\text{SO}_2\text{R}'')$,
 XNHCOR^4 , XNHCOOR^4 , XNHCONHR^4 , or R^4 , whereby two substituents R^3 , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, butane-1,4-diyl.
19. Use according to ~~claims 15-18~~ claim 15, whereby in general formula II R^4 and R^4' , independently of one another, mean CF_3 , C_2F_5 , C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, (C_{1-3} alkyl- C_{3-6} cycloalkyl), C_{1-3} alkylaryl, C_{1-3} alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F , Cl , Br , CH_3 , C_2H_5 , NO_2 , OCH_3 , OC_2H_5 , CF_3 , C_2F_5 or else can carry an annelated methanediylbisoxo or ethane-1,2-diylbisoxo group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl.

20. Use according to ~~claims 15-19~~ claim 15, whereby in general formula II R⁵ and R^{5'}, independently of one another, can be C₁₋₆ alkyl,
whereby a carbon atom can be exchanged for O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl, C₃₋₇ cycloalkyl-C₀₋₃ alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, whereby the mentioned C₁₋₆ alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O,
whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF₃, OH, O C₁₋₃ alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl, CF₃, CH₃, C₂H₅, OCH₃, OC₂H₅, or R⁵ and R^{5'} together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C₁₋₄ alkyl, C₁₋₄ alkoxy-C₀₋₂ alkyl, C₁₋₄ alkoxy-carbonyl, amino-carbonyl or phenyl.

21. Use according to ~~claims 15-20~~ claim 15, whereby in general formula II A means C₁₋₁₀ alkanediyl; C₂₋₁₀ alkenediyl, C₂₋₁₀ alkinediyl, (C₀₋₅ alkanediyl-C₃₋₇ cycloalkanediyl-C₀₋₅ alkanediyl), or (C₀₋₅ alkanediyl-heteroarylene-C₀₋₅ alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br, CH₃, C₂H₅, NO₂, OCH₃, OC₂H₅, CF₃, C₂F₅, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C₁₋₃ alkyl or C₁₋₃ alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N C₁₋₃ alkyl, N C₁₋₃ alkanoyl, NSO₂ C₁₋₃ alkyl,

and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C₁₋₃ alkyl, O C₁₋₃ alkanoyl, =O, NH₂, NH C₁₋₃ alkyl, N (C₁₋₃ alkyl)₂, NH C₁₋₃ alkanoyl, N (C₁₋₃ alkyl) (C₁₋₃ alkanoyl), NHCOO C₁₋₃ alkyl, NHCONH C₁₋₃ alkyl, NHSO₂ C₁₋₃ alkyl, SH, S C₁₋₃ alkyl.

22. Use according to ~~claims 15-21~~ claim 15, whereby in general formula II
B means hydrogen, OH, OCOR⁵, OCONHR⁵, OCOOR⁵, COOH, COOR⁵, CONH₂, CONHR⁵, CONR⁵R⁵, CONHOH, CONHOR⁵, or tetrazolyl, in each case bonded to a carbon atom of group **A**.
23. Use according to ~~claims 15-22~~ claim 15, whereby in general formula II,
X means a bond or CH₂.
24. Use according to ~~claims 15-23~~ claim 15, whereby in general formula II,
Y means a bond, O, S, NH, NR⁴, NCOR⁴ or NSO₂R⁴.